Literature DB >> 2210873

Inhibition of IgE-mediated N-acetylglucosaminidase and serotonin release from rat basophilic leukemia cells (RBL-2H3) by tenidap: a novel anti-inflammatory agent.

M J Conklyn1, S B Kadin, H J Showell.   

Abstract

Tenidap [(Z)-5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H- indole-1-carboxamide] is a novel anti-inflammatory compound of the oxindole class that currently is undergoing clinical evaluation in man. Here we demonstrate that tenidap inhibits (IC50 = approximately 10 microM) IgE-mediated secretion of granule constituents from the rat mast cell tumor line RBL-2H3. The inhibitory effect is rapid in onset, readily reversible, and appears to be unique when compared to a representative selection of other acidic (carboxylic acids, pyrazoles and oxicams) nonsteroidal anti-inflammatory compounds.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2210873     DOI: 10.1159/000235143

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  4 in total

1.  Novel oxindole derivatives and their biological activity.

Authors:  J Strigácová; D Hudecová; M Mikulásová; L Varecka; A Lásiková; D Végh
Journal:  Folia Microbiol (Praha)       Date:  2001       Impact factor: 2.099

2.  Tenidap, a structurally novel drug for the treatment of arthritis: antiinflammatory and analgesic properties.

Authors:  P F Moore; D L Larson; I G Otterness; A Weissman; S B Kadin; F J Sweeney; J D Eskra; A Nagahisa; M Sakakibara; T J Carty
Journal:  Inflamm Res       Date:  1996-02       Impact factor: 4.575

3.  Evaluation of Tenidap (CP-66,248) on human neutrophil arachidonic acid metabolism, chemotactic potential and clinical efficacy in the treatment of rheumatoid arthritis.

Authors:  D M Smith; J A Johnson; R Loeser; R A Turner
Journal:  Agents Actions       Date:  1990-08

4.  Inhibition of mediator release in RBL-2H3 cells by some H1-antagonist derived anti-allergic drugs: relation to lipophilicity and membrane effects.

Authors:  M J Fischer; J J Paulussen; D A Horbach; E P Roelofsen; J C van Miltenburg; N J de Mol; L H Janssen
Journal:  Inflamm Res       Date:  1995-02       Impact factor: 4.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.